reports
Chocoladefabriken Lindt & Sprungli AG: 1 director
A director at Chocoladefabriken Lindt & Sprungli AG sold 526 shares at 10,685.551CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Aksa Akrilik Kimya Sanayii A S: 1 director
A director at Aksa Akrilik Kimya Sanayii A S bought 383,000 shares at 120.300TRY and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
Alm. Brand A/S – Weekly report on share buybacks
Alm. Brand A/S – Weekly report on share buybacks Alm. Brand A/S share buy-back program Transactions during 06 May 2024 – 08 May 2024On 5 December 2023, Alm. Brand A/S announced a share buy-back program of up to DKK 250 million, as described in company announcement no. 23/2023. On 8 February 2024, Alm. Brand A/S announced an increase of the existing share buy-back programme by DKK 100 million to DKK 350 million and extension of the period for the programme until and including 30 September 2024, as described in company announcement no. 09/2024. The program is carried out in accordance with ...
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month: The Citizens JMP Life Sciences Conference (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside cha...
Avalo Reports First Quarter 2024 Financial Results and Provides Busine...
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2024. “Over the past month we have made considerable progress toward initiating our planned Phase 2 trial of AVTX-009 in hid...
Spectral Medical Announces First Quarter Results and Provides Corporat...
Spectral Medical Announces First Quarter Results and Provides Corporate Update Tigris Trial Enrollment Reaches 106 Patients Bought Deal Financing Expected to Fund Completion of Tigris Trial Enrollment TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2024, and provided a corporate update. Spectral has continued its significant progress throu...
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results – Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – – Preliminary Phase 2 results for VP-315 in the treatment of basal cell carcinoma (BCC) expected in the second quarter of 2024 – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company develop...
Titan Medical Reports Financial Results for the First Quarter 2024
Titan Medical Reports Financial Results for the First Quarter 2024 TORONTO, Ontario, May 13, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), today reported financial results for the three months ended March 31, 2024. Recent Activities: On March 18, 2024, the Company announced it has entered into a definitive amalgamation agreement (the “Definitive Agreement”) with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction (the “Transaction”). Under the terms of the Definitive Agreement, a newly incorporated and whol...
Annovis Bio Provides Corporate Updates and Announces First Quarter 202...
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results. Clinical Updates AD Phase II/III Study On April 29, Annovis announced statistically significant Phase II/III data in patients with early Alzheimer’s disease (AD). Significantly higher rate of improvement...
BridgeBio Pharma Presents Additional Data and Analyses from its Phase ...
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population - In a pre-specified Cochran-Mantel-Haenszel sensitivity analysis applied to the entire intention-to-treat (ITT) population of the study (N=632), acoramidis significantly reduced all-cause mortality (p=0.04), with no safety signals of potential clinical concern - Among ATTRibute-CM participants...
dLab erhåller en order om cirka 800 000 SEK av Gotlands Energi AB
dLab erhåller en order om cirka 800 000 SEK av Gotlands Energi AB Lund, 13 maj 2024 Dlaboratory Sweden AB (publ) meddelar idag att bolaget har erhållit en order om cirka 800 000 SEK från Gotlands Energi AB. Ordern avser dLabs intelligenta platform där Gotlands Energi väljer att påbörja övervakning av sitt elnät med hjälp av applikationerna dAnalyzer och dQuality för att förbättra leveranskvalitén i elnätet. Ordern kommer att levereras och installeras under augusti 2024 och medför en engångsintäkt om cirka 660 000 SEK, samt en årligt åtekommande avgiftsintäkt om ytterligare cirka 130 00...
Leading Independent Proxy Advisory Firm ISS Recommends Shareholders Vo...
Leading Independent Proxy Advisory Firm ISS Recommends Shareholders Vote “FOR” All of Crown Castle’s Director Nominees Crown Castle Urges Shareholders to Vote “FOR” ONLY Crown Castle’s 12 Highly Qualified Nominees on the WHITE Proxy Card or Voting Instruction Form Today HOUSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) (“Crown Castle” or the “Company”) today announced that Institutional Shareholder Services (ISS), a leading independent proxy advisory firm, has recommended that shareholders vote on the WHITE proxy card or voting instruction form “FOR” ONLY all 12 of...
Avicanna Announces Results of Study in Patients with Epidermolysis Bul...
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa The study conducted at The Hospital for Sick Children evaluated wound healing, pain, and itch.55% of patients enrolled in Study reported improvements in wound healing, 45% displayed wound stability. TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the completion of the retrospective obser...
Plus Therapeutics to Announce First Quarter Financial Results and Host...
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024 AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 15, 2024, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and pr...
MiNK Therapeutics Announces $5.8 Million Private Placement and Appoint...
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board Observer NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other i...
Enovix Begins Customer Sampling of EX-1M Batteries
Enovix Begins Customer Sampling of EX-1M Batteries FREMONT, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- (“Enovix”) (Nasdaq: ENVX), a global high-performance battery company, today announced that it has begun customer sampling of its breakthrough EX-1M battery. Initial EX-1M samples were built and tested at the company’s facility in Fremont for IoT and smartphone customers. Enovix plans to build a larger number of EX-1M samples from its Agility Line at Fab2 in Malaysia later in the second quarter of 2024. “We set out on an ambitious plan last year to build a battery that would meet the dem...
Dassault Systèmes: declaration of the number of outstanding shares and...
Dassault Systèmes: declaration of the number of outstanding shares and voting rights as of April 30, 2024 Press ReleaseVELIZY-VILLACOUBLAY, France — May 13, 2024 Declaration of the number of outstanding shares and voting rights as of April 30, 2024 (Euronext Paris: FR0014003TT8, DSY.PA) today announced below the total number of its outstanding shares and voting rights as of April 30, 2024, according to articles 223-16 and 221-3 of the General Regulation of the Autorité des marchés financiers. Number of outstanding shares: 1,338,731,279 Number of voting rights*: 2,007,958,682 *The tota...
- Christian ZEGBE
Flash Hebdo du 29 avril au 03 mai 2024
La tendance du marché Actions Après trois cotations hebdomadaires positives, la Bourse Régionale des Valeurs Mobilières clôture sa 18ème semaine de cotation de l’année 2024 sur une note négative. En effet, l’indice BRVM-Composite s’est inscrit en baisse de 0,30% pour s’établir à 219,19 points portant ainsi sa performance depuis le début de l’année à +2,35%. Dans la même veine, le BRVM 30 et le BRVM Prestige, ont respectivement régressé de 0,50% à 119,98 points et de 0,36% à 103,10 points...
- Christian ZEGBE
Flash Hebdo du 06 au 10 mai 2024
La tendance du marché Actions Malgré trois séances en baisse contre une en hausse, la Bourse Régionale des Valeurs Mobilières a clôturé sa 19ème semaine de cotation de l’année 2024 sur une note positive. En effet, l’indice BRVM-Composite s’est adjugé 0,33% pour s’établir à 219,91 points portant ainsi sa performance depuis le début de l’année à +2,69%. Dans la même lignée, le BRVM 30 et le BRVM Prestige, ont respectivement progressé de 0,26% à 110,27 points et de 0,45% à 103,56 points. L...
- David Havrlant
Czech price growth surprised in April; pace of rate cuts likely to slo...
Headline inflation in April jumped to 2.9% year-on-year, significantly higher than both the Czech National Bank forecast and market expectations. This confirms the Bank Board's reasons for caution in cutting interest rates, with monetary easing likely to slow down
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.